Regeneron, Roche, Sanofi, City of Hope antibodies news
Sanofi and Regeneron filed an inter partes review (IPR) petition and a lawsuit challenging two Cabilly patents from Roche’s Genentech Inc. unit and the City of Hope. Sanofi and Regeneron said they filed their suit in response to the “imminent threat of a lawsuit” by Genentech for infringement. Both Cabilly patents, which cover methods of antibody production, have been the target of several district court suits.
The IPR filed challenges Cabilly II (U.S. Patent No. 6,331,415), which expires in 2018. The petition argues the patent’s claims were anticipated in prior art. In 2009, the U.S. Patent and Trademark Office (PTO) confirmed the patentability of all claims in Cabilly II after a re-examination proceeding. (see BioCentury, March 2, 2009). ...